DBV Technologies (NASDAQ:DBVT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVTGet Rating) in a research note published on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Kepler Capital Markets upgraded shares of DBV Technologies from a hold rating to a buy rating and set a €6.00 ($6.12) price objective on the stock in a report on Thursday, August 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, DBV Technologies has a consensus rating of Hold and an average target price of $5.63.

DBV Technologies Price Performance

NASDAQ DBVT opened at $1.38 on Tuesday. DBV Technologies has a 12 month low of $1.15 and a 12 month high of $3.43. The stock has a market capitalization of $259.51 million, a P/E ratio of -2.51 and a beta of 1.43. The firm’s 50-day moving average is $1.65 and its two-hundred day moving average is $1.98.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in DBV Technologies by 16.5% during the 1st quarter. BlackRock Inc. now owns 687,341 shares of the company’s stock worth $1,093,000 after buying an additional 97,412 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of DBV Technologies during the second quarter worth $26,000. BNP Paribas Arbitrage SA acquired a new stake in shares of DBV Technologies in the second quarter valued at $49,000. ExodusPoint Capital Management LP purchased a new position in DBV Technologies in the second quarter valued at $352,000. Finally, Fairmount Funds Management LLC grew its stake in DBV Technologies by 46.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 7,064,964 shares of the company’s stock worth $12,505,000 after purchasing an additional 2,233,809 shares in the last quarter. Hedge funds and other institutional investors own 27.55% of the company’s stock.

DBV Technologies Company Profile

(Get Rating)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.

Further Reading

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.